Free Trial

Medpace (MEDP) Stock Price, News & Analysis

+15.87 (+3.77%)
(As of 07/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
297,694 shs
Average Volume
229,393 shs
Market Capitalization
$13.54 billion
P/E Ratio
Dividend Yield
Price Target

Medpace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
1.9% Upside
$445.29 Price Target
Short Interest
3.87% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.82mentions of Medpace in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$11.82 M Sold Last Quarter
Proj. Earnings Growth
From $11.29 to $13.13 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.75 out of 5 stars

Medical Sector

54th out of 894 stocks

Commercial Physical Research Industry

3rd out of 11 stocks

MEDP stock logo

About Medpace Stock (NASDAQ:MEDP)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Stock Price History

MEDP Stock News Headlines

Medpace Holdings, Inc. Reports Second Quarter 2024 Results
What Wall Street expects from Medpace's earnings
J.P. Morgan’s warns of "most predictable crisis in history"
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Medpace Q2 2024 Earnings Preview
Medpace (MEDP) Scheduled to Post Earnings on Monday Upgrades Medpace (NASDAQ:MEDP) to Buy
J.P. Morgan’s warns of "most predictable crisis in history"
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Medpace: Clear Winner If China Blockade Succeeds
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$282.81 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$10.45 per share
Book Value
$18.22 per share


Free Float
Market Cap
$13.54 billion
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

MEDP Stock Analysis - Frequently Asked Questions

How have MEDP shares performed this year?

Medpace's stock was trading at $306.53 on January 1st, 2024. Since then, MEDP shares have increased by 42.6% and is now trading at $437.18.
View the best growth stocks for 2024 here

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings results on Monday, April, 22nd. The company reported $3.20 earnings per share for the quarter, beating analysts' consensus estimates of $2.45 by $0.75. The company's revenue was up 17.7% compared to the same quarter last year.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's top institutional investors include Riverbridge Partners LLC (1.73%), Westwind Capital (1.23%), Boston Trust Walden Corp (0.51%) and Assenagon Asset Management S.A. (0.28%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Ashley M Keating, Robert O Kraft and Tom C King.
View institutional ownership trends

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), (JD), Advanced Micro Devices (AMD) and Bilibili (BILI).

This page (NASDAQ:MEDP) was last updated on 7/22/2024 by Staff

From Our Partners